ArticleFrontiers in nutrition2026
Prognostic value of the cardiometabolic index for cardiovascular outcomes in patients with type 2 diabetes mellitus.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Cardiometabolic Index (CMI) serves as a measurable indicator capable of concurrently reflecting the presence of metabolic disorders and the status of central obesity. The aim of this study is to evaluate the association between the CMI and the risk of developing major adverse cardiovascular events (MACEs) and all-cause mortality in patients with type 2 diabetes mellitus (T2DM). Methods: This Results: Over a median follow-up period of 8.82 years, 1,791 (17.74%) participants experienced MACEs, and 1,914 (18.96%) all-cause mortality were recorded. After adjusting for traditional cardiovascular risk factors, multivariate Cox proportional hazards regression analysis demonstrated a significant association between CMI and the risk of MACEs and all-cause mortality. Incorporating CMI into the conventional risk model improved the predictive efficacy for MACEs and all-cause mortality. Conclusions: Elevated CMI is associated with an increased risk of MACEs and all-cause mortality in patients with T2DM. Furthermore, CMI improves the predictive performance for MACEs and all-cause mortality risk in this patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.